HIV Protease
-
Subject Areas on Research
- A simple Escherichia coli system for monitoring HIV protease activity: analysis of two temperature-sensitive protease mutants.
- Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon.
- Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
- Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.
- Developing an HIV vaccine.
- Development of a novel screen for protease inhibitors.
- Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.
- Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
- Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
- HIV evolutionary genetics.
- Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients.
- Identification of cis-acting repressor activity within human immunodeficiency virus type 1 protease sequences.
- Impact of genotypic resistance testing on physician selection of antiretroviral therapy.
- Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells.
- Lack of protease inhibitor resistance following treatment failure--too good to be true?
- Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
- Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
- Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection.
- Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir.
- Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection.
- Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O.
- Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.
- Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers.
- Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
- Sculpting proteins interactively: continual energy minimization embedded in a graphical modeling system.
- Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay.
- Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease.
- Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.